Skip to main content
PMC home page
Epidemiology and Infection logoLink to Epidemiology and Infection
. 1994 Feb;112(1):125–131. doi: 10.1017/s0950268800057484

Aminoglycoside resistance patterns of Serratia marcescens strains of clinical origin.

R Coria-Jiménez 1, C Ortiz-Torres 1
PMCID: PMC2271489  PMID: 8119351

Abstract

Aminoglycoside resistance patterns of 147 Serratia marcescens strains of clinical origin were studied. All strains analysed belonged to three different bacterial populations. The periods of study and the institutions the strains were isolated from correlated significantly with the resistance patterns shown by the strains. The most frequent resistance patterns found were the following: ACC (6')-I at the Hospital Infantil de México (Children's Hospital of México), and ANT (2'') + AAC(6')-I at the Instituto Nacional de Pediatría (INPed or National Institute of Pediatrics) in Mexico City. Furthermore, the isolation frequency of aminoglycoside-sensitive strains decreased remarkably at the INPed over a 12-year period. These results suggest that there has been a selection of Serratia marcescens strains that are very resistant to aminoglycosides.

Full text

PDF
125

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bar-Ness R., Rosenberg M. Putative role of a 70 kDa outer-surface protein in promoting cell-surface hydrophobicity of Serratia marcescens RZ. J Gen Microbiol. 1989 Aug;135(8):2277–2281. doi: 10.1099/00221287-135-8-2277. [DOI] [PubMed] [Google Scholar]
  2. Bollmann R., Halle E., Sokolowska-Köhler W., Grauel E. L., Buchholz P., Klare I., Tschäpe H., Witte W. Nosocomial infections due to Serratia marcescens--clinical findings, antibiotic susceptibility patterns and fine typing. Infection. 1989 Sep-Oct;17(5):294–300. doi: 10.1007/BF01650711. [DOI] [PubMed] [Google Scholar]
  3. Coria-Jiménez R., Ortiz-Torres C., Cruz-Camarillo R. Biotyping of Serratia marcescens strains of clinical origin. Rev Latinoam Microbiol. 1992 Oct-Dec;34(4):253–258. [PubMed] [Google Scholar]
  4. Coria-Jiménez V. R., Villa-Tanaka L., Ortíz-Torres C. Partial characterization of Serratia marcescens nosocomial strains. Arch Invest Med (Mex) 1991 Jul-Dec;22(3-4):273–278. [PubMed] [Google Scholar]
  5. Dang P., Gutmann L., Quentin C., Williamson R., Collatz E. Some properties of Serratia marcescens, Salmonella paratyphi A, and Enterobacter cloacae with non-enzyme-dependent multiple resistance to beta-lactam antibiotics, aminoglycosides, and quinolones. Rev Infect Dis. 1988 Jul-Aug;10(4):899–904. doi: 10.1093/clinids/10.4.899. [DOI] [PubMed] [Google Scholar]
  6. Farmer J. J., 3rd, Davis B. R., Hickman F. W., Presley D. B., Bodey G. P., Negut M., Bobo R. A. Detection of Serratia outbreaks in hospital. Lancet. 1976 Aug 28;2(7983):455–459. doi: 10.1016/s0140-6736(76)92539-3. [DOI] [PubMed] [Google Scholar]
  7. Fujimaki K., Fujii T., Aoyama H., Sato K., Inoue Y., Inoue M., Mitsuhashi S. Quinolone resistance in clinical isolates of Serratia marcescens. Antimicrob Agents Chemother. 1989 May;33(5):785–787. doi: 10.1128/aac.33.5.785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Goldstein F. W., Gutmann L., Williamson R., Collatz E., Acar J. F. In vivo and in vitro emergence of simultaneous resistance to both beta-lactam and aminoglycoside antibiotics in a strain of Serratia marcescens. Ann Microbiol (Paris) 1983 May-Jun;134A(3):329–337. [PubMed] [Google Scholar]
  9. Hechler U., van den Weghe M., Martin H. H., Frère J. M. Overproduced beta-lactamase and the outer-membrane barrier as resistance factors in Serratia marcescens highly resistant to beta-lactamase-stable beta-lactam antibiotics. J Gen Microbiol. 1989 May;135(5):1275–1290. doi: 10.1099/00221287-135-5-1275. [DOI] [PubMed] [Google Scholar]
  10. König W., Faltin Y., Scheffer J., Schöffler H., Braun V. Role of cell-bound hemolysin as a pathogenicity factor for Serratia infections. Infect Immun. 1987 Nov;55(11):2554–2561. doi: 10.1128/iai.55.11.2554-2561.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Larson T. A., Garrett C. R., Gerding D. N. Frequency of aminoglycoside 6'-N-acetyltransferase among Serratia species during increased use of amikacin in the hospital. Antimicrob Agents Chemother. 1986 Jul;30(1):176–178. doi: 10.1128/aac.30.1.176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mendoza M. C., Blanco M. G., Javier Mendez F., Hardisson C. Evolution de la résistance aux aminosides chez des souches hospitalières de Serratia. Pathol Biol (Paris) 1984 Sep;32(7):750–754. [PubMed] [Google Scholar]
  13. Poole K., Braun V. Influence of growth temperature and lipopolysaccharide on hemolytic activity of Serratia marcescens. J Bacteriol. 1988 Nov;170(11):5146–5152. doi: 10.1128/jb.170.11.5146-5152.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Rubens C. E., McGee Z. A., Farrar W. E., Jr Loss of an aminoglycoside resistance plasmid by Serratia marcescens during treatment of meningitis with amikacin. J Infect Dis. 1980 Mar;141(3):346–350. doi: 10.1093/infdis/141.3.346. [DOI] [PubMed] [Google Scholar]
  15. Saito H., Elting L., Bodey G. P., Berkey P. Serratia bacteremia: review of 118 cases. Rev Infect Dis. 1989 Nov-Dec;11(6):912–920. doi: 10.1093/clinids/11.6.912. [DOI] [PubMed] [Google Scholar]
  16. Sanders C. C., Watanakunakorn C. Emergence of resistance to beta-lactams, aminoglycosides, and quinolones during combination therapy for infection due to Serratia marcescens. J Infect Dis. 1986 Mar;153(3):617–619. doi: 10.1093/infdis/153.3.617. [DOI] [PubMed] [Google Scholar]
  17. Sanders W. E., Jr, Sanders C. C. Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. Rev Infect Dis. 1988 Jul-Aug;10(4):830–838. doi: 10.1093/clinids/10.4.830. [DOI] [PubMed] [Google Scholar]
  18. Shaw K. J., Hare R. S., Sabatelli F. J., Rizzo M., Cramer C. A., Naples L., Kocsi S., Munayyer H., Mann P., Miller G. H. Correlation between aminoglycoside resistance profiles and DNA hybridization of clinical isolates. Antimicrob Agents Chemother. 1991 Nov;35(11):2253–2261. doi: 10.1128/aac.35.11.2253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Shaw K. J., Rather P. N., Sabatelli F. J., Mann P., Munayyer H., Mierzwa R., Petrikkos G. L., Hare R. S., Miller G. H., Bennett P. Characterization of the chromosomal aac(6')-Ic gene from Serratia marcescens. Antimicrob Agents Chemother. 1992 Jul;36(7):1447–1455. doi: 10.1128/aac.36.7.1447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Shimizu K., Kumada T., Hsieh W. C., Chung H. Y., Chong Y., Hare R. S., Miller G. H., Sabatelli F. J., Howard J. Comparison of aminoglycoside resistance patterns in Japan, Formosa, and Korea, Chile, and the United States. Antimicrob Agents Chemother. 1985 Aug;28(2):282–288. doi: 10.1128/aac.28.2.282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sifuentes-Osornio J., Ruiz-Palacios G. M., Gröschel D. H. Analysis of epidemiologic markers of nosocomial Serratia marcescens isolates with special reference to the Grimont biotyping system. J Clin Microbiol. 1986 Feb;23(2):230–234. doi: 10.1128/jcm.23.2.230-234.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Traub W. H., Bauer D. Outer membrane protein alterations in Serratia marcescens resistant against aminoglycoside and beta-lactam antibiotics. Chemotherapy. 1987;33(3):172–176. doi: 10.1159/000238491. [DOI] [PubMed] [Google Scholar]
  23. Traub W. H., Spohr M., Bauer D. Plasmid-independent resistance of 'gray' colony variants of a strain of Serratia marcescens resistant to amikacin, cefotaxime and lamoxactam. Chemotherapy. 1983;29(4):265–274. doi: 10.1159/000238208. [DOI] [PubMed] [Google Scholar]
  24. Yu V. L. Serratia marcescens: historical perspective and clinical review. N Engl J Med. 1979 Apr 19;300(16):887–893. doi: 10.1056/NEJM197904193001604. [DOI] [PubMed] [Google Scholar]

Articles from Epidemiology and Infection are provided here courtesy of Cambridge University Press

RESOURCES